ArticleJournal of cachexia, sarcopenia and muscle2021
Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS.
Article in Journal of cachexia, sarcopenia and muscle, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 38 citations in OpenAlex.
- Upacicalcet Preserves Albumin Levels in Patients on Hemodialysis with Secondary Hyperparathyroidism: A post hoc Analysis of a Randomized Trial.American journal of nephrology · 2026Trial
- Bone turnover markers associated with cognitive dysfunction in patients undergoing hemodialysis: a cross-sectional study.JBMR plus · 2026Article
- Low Time-Weighted Parathyroid Hormone Is Associated with Malnutrition-Inflammation and Functional Dependence in Maintenance Hemodialysis.Nutrients · 2026Article
- Prognosis comparison in chronic kidney disease stages 4-5 patients with low parathyroid hormone level due to different causes.BMC nephrology · 2026Observational
- Association of calcimimetic use with lower mortality in elderly patients with low body mass index and inflammation compared with non-users.Scientific reports · 2026Article
- Parathyroid hormone enhances appetite and fails to reduce adiposity in ob/ob mice.Pflugers Archiv : European journal of physiology · 2026Article
- Article
- Association of Oral Frailty with Physical Frailty and Malnutrition in Patients on Peritoneal Dialysis.Nutrients · 2025Article
- Recovery time is associated with the onset of cardiovascular disease in Japanese patients undergoing maintenance hemodialysis.Clinical and experimental nephrology · 2025Article
- Association between serum intact parathyroid hormone and survival in dialysis patients.International urology and nephrology · 2025Article
- Platelet count has a U-shaped association with mortality in hemodialysis patients.Scientific reports · 2024Article
- Lower Parathyroid Hormone Levels are Associated With Reduced Fracture Risk in Japanese Patients on Hemodialysis.Kidney international reports · 2024Article
- Association between Chronic Kidney Disease-Mineral and Bone Disorder Biomarkers and Symptom Burden in Older Patients with Advanced Chronic Kidney Disease: Results from the EQUAL Study.Clinical journal of the American Society of Nephrology : CJASN · 2024Article
- A novel nomogram for predicting the risk of persistent hyperparathyroidism after kidney transplantation.Endocrine · 2024Article
- Crosstalk between kidney and bone: insights from CKD-MBD.Journal of bone and mineral metabolism · 2024Review
- Roles of Parathyroid Hormone and Fibroblast Growth Factor 23 in Advanced Chronic Kidney Disease.Endocrinology and metabolism (Seoul, Korea) · 2024Review
- Unusual body weight loss due to primary hyperparathyroidism: A case study with literature review.Heliyon · 2024Article
- Hyperparathyroidism, Serum Phosphorus and Dietary Intake in Hemodialysis Patients: Is There a Novel Relationship?International journal of molecular sciences · 2024Observational
- Association of serum intact parathyroid hormone levels with sarcopenia in patients undergoing peritoneal dialysis.Frontiers in medicine · 2024Article
- Complications after radiofrequency ablation of hyperparathyroidism secondary to chronic kidney disease.Renal failure · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWasting is a common complication of kidney failure that leads to weight loss and poor outcomes. Recent experimental data identified parathyroid hormone (PTH) as a driver of adipose tissue browning and wasting, but little is known about the relations among secondary hyperparathyroidism, weight loss, and risk of mortality in dialysis patients.
methodsWe included 42,319 chronic in-centre haemodialysis patients from the Dialysis Outcomes and Practice Patterns Study phases 2-6 (2002-2018). Linear mixed models were used to estimate the association between baseline PTH and percent weight change over 12 months, adjusting for country, demographics, comorbidities, and labs. Accelerated failure time models were used to assess 12 month weight loss as a mediator between baseline high PTH and mortality after 12 months.
resultsBaseline PTH was inversely associated with 12 month weight change: 12 month weight loss >5% was observed in 21%, 18%, 18%, 17%, 15%, and 14% of patients for PTH ≥600 pg/mL, 450-600, 300-450, 150-300, 50-150, and <50 pg/mL, respectively. In adjusted analyses, 12 month weight change compared with PTH 150-299 pg/mL was -0.60%, -0.12%, -0.10%, +0.15%, and +0.35% for PTH ≥600, 450-600, 300-450, 50-150, and <50 pg/mL, respectively. This relationship was robust regardless of recent hospitalization and was more pronounced in persons with preserved appetite. During follow-up after the 12 month weight measure [median, 1.0 (interquartile range, 0.6-1.7) years; 6125 deaths], patients with baseline PTH ≥600 pg/mL had 11% [95% confidence interval (CI), 9-13%] shorter lifespan, and 18% (95% CI, 14-23%) of this effect was mediated through weight loss ≥2.5%.
conclusionsSecondary hyperparathyroidism may be a novel mechanism of wasting, corroborating experimental data, and, among chronic dialysis patients, this pathway may be a mediator between elevated PTH levels and mortality. Future research should determine whether PTH-lowering therapy can limit weight loss and improve longer term dialysis outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.